Option Care Health Inc - Company Profile
Powered by 
All the sales intelligence you need on Option Care Health Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Option Care Health Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Option Care Health Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Option Care Health Inc (Option Care Health) is a healthcare service provider that offers infusion therapy and other ancillary healthcare services. The company provides home infusion services and alternative site infusion services. Its services consist of anti-infectives, bleeding disorder therapies, immunoglobulin therapy, nutrition support, and other therapies for chronic and acute conditions. The company also provides infusion therapy services such as nursing support, clinical management, and care coordination. It focuses on improving the quality of care and reducing patient healthcare costs. The company has operations in Florida, California, Georgia, Ohio, Delaware, Illinois, Kentucky, Massachusetts, and Minnesota. Option Care Health is headquartered in Bannockburn, Illinois, the US.
Headquarters
United States of America
Address
3000 Lakeside Drive, Suite 300N, Bannockburn, Illinois, 60015
Website
www.optioncarehealth.com
Telephone
1 312 9402443
No of Employees
6,528
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OPCH (NASD)
Revenue (2024)
$5.6B
13%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-2%
(2024 vs 2023)
Market Cap*
$3.4B
Net Profit Margin (2024)
XYZ
-13.4%
(2024 vs 2023)
* As of and is in US$
Option Care Health Inc premium industry data and analytics
Products and Services
| Services | Brands |
|---|---|
| Anti-Infective Therapy | - |
| Immunoglobulin Therapy | Option Care Health |
| Cardiac Care | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In August, the company entered into a partnership with Quince Therapeutics for the development of encapsulated dexamethasone sodium phosphate for Ataxia-Telangiectasia treatment. |
| 2024 | Contracts/Agreements | In August, the company entered into an agreement with Palantir Technologies Inc, to adopt its Artificial Intelligence Platform (AIP) for digital transformation. |
| 2024 | Contracts/Agreements | In January, the company entered into a multi-year commercial partnership with Palantir Technologies for its software to be leveraged in the company to support patient outcomes and increase efficiency. |
Competitor Comparison
| Key Parameters | Option Care Health Inc | CVS Health Corp | BrightSpring Health Services | Accredo Health Group Inc | Coram CVS/specialty Infusion Services |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Bannockburn | Woonsocket | Louisville | Memphis | Denver |
| State/Province | Illinois | Rhode Island | Kentucky | Tennessee | Colorado |
| No. of Employees | 6,528 | 300,000 | 23,500 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Harry M. Jansen Kraemer, Jr. | Chairman | Executive Board | 2019 | 71 |
| John C. Rademacher | Director; President; Chief Executive Officer | Executive Board | 2019 | 59 |
| Meenal Sethna | Chief Financial Officer; Executive Vice President | Senior Management | 2025 | - |
| Luke Whitworth | Chief Operating Officer | Senior Management | 2023 | 45 |
| Alyssa Moy | Chief Information Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer